Application of SELDI-TOF-MS in establishing a model for predicting radiotherapy response of hypopharyngeal cancers.
- Author:
Wen-dong TIAN
1
;
Zong-yuan ZENG
;
Wen-bin YU
;
Xiang-ping LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; analysis; Carcinoma, Squamous Cell; genetics; radiotherapy; Female; Humans; Hypopharyngeal Neoplasms; genetics; radiotherapy; Male; Middle Aged; Models, Biological; Proteome; analysis; Radiation Tolerance; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; methods
- From: Journal of Southern Medical University 2010;30(6):1282-1287
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo detect the serum proteomic fingerprints in patients with hypopharyngeal squamous cell carcinoma (HPSCC) by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) protein chip array technique.
METHODSThe serum samples were obtained from 58 HPSCC patients for protein expression analysis using SELDI-TOF Protein Chip technique and cation-exchange (CM10) protein array. All the spectra were compared and the qualified mass peaks with mass-to-charge ratios (m/z) between 1 and 70 kD were autotimatically detected. The tree analysis pattern was generated using Biomarker Patterns Software.
RESULTSThe protein profiles of HPSCC serum were analyzed according to the clinical and pathological features of the patients and their treatment response. No significant difference was noted in the serum proteins between HPSCC patients with different statuses of cervical lympha node metastasis (P>0.05), and the difference between well differentiated and poorly differentiated HPSCC was only minor. No significant difference was found in the serum proteins between chemotherapy-sensitive patients and the insensitive patients (P>0.05), but 5 proteins were identified to be overexpressed in the sensitive patients (P < / = 0.05). Radiotherapy-sensitive HPSCC patients were segregated from the insensitive group with a sensitivity of 86.67% and specificity of 100%.
CONCLUSIONThe serum protein at the m/z value of 6115.74 is overexpressed in radiotherapy-sensitive HPSCC patients. Serum protein profiling allows the prediction of radiotherapy response in HPSCC patients, and the identified proteins may serve as candidate biomarkers for predicting the radiotherapy sensitivity of HPSCC.